CN110876756A - Ointment for treating onychomycosis - Google Patents
Ointment for treating onychomycosis Download PDFInfo
- Publication number
- CN110876756A CN110876756A CN201911304390.0A CN201911304390A CN110876756A CN 110876756 A CN110876756 A CN 110876756A CN 201911304390 A CN201911304390 A CN 201911304390A CN 110876756 A CN110876756 A CN 110876756A
- Authority
- CN
- China
- Prior art keywords
- parts
- ointment
- mass
- following raw
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Abstract
The application provides an ointment for treating onychomycosis. The ointment is prepared from the following raw materials in parts by mass: 5-15 parts of salicylic acid, 5-9 parts of benzoic acid, 15-25 parts of boric acid, 20-30 parts of ketoconazole and 15-25 parts of auxiliary materials, wherein the auxiliary materials are selected from any one or a combination of more of talcum powder, propylene glycol, myristic acid isopropanol, cetyl alcohol, stearyl alcohol and sorbitan stearate. Thus, the ointment adopts a chemical agent combination scheme with specific combination so as to inhibit germs more effectively.
Description
Technical Field
The application relates to an ointment, in particular to an ointment for treating onychomycosis.
Background
Onychomycosis, a modern medical term called onychomycosis, is a chronic infectious nail disease that occurs by the invasion of dermatophytes, yeasts and fungi into the nail plate and nail bed below the nail plate. Onychomycosis is a common disease and frequently encountered disease of dermatology, and is a disease which is relatively difficult to treat. The most obvious manifestation of onychomycosis is onychomycosis, which is a common off-white color, and can also be seen as brown, taupe or dark brown. The manifestations associated with these abnormal colors may also include thickening, embrittlement, flaking, bruising, yellowing, hollowing, uneven periungual, incomplete nail, etc., and some diseases may be accompanied by inflammation of the nail groove, local inflammation and pain, and serious diseases may cause serious systemic symptoms of deep tissue and organ infection such as erysipelas or cellulitis, even endanger life. Tinea unguium of siblings of women can be infected to the pudendum to form gynecological diseases such as mycotic vaginitis and Candida albicans vaginitis which are difficult to cure. The disease has very slow course and infectivity, if the disease is not treated in time, the disease can spread and affect all nails or infect other people, the appearance is seriously affected, the communication and normal life of people are affected, and the disease can also bring the harm to the whole body.
Therefore, there is a need for an effective ointment for treating onychomycosis.
Disclosure of Invention
An object of the present application is to provide an ointment for treating onychomycosis, wherein the ointment adopts a specific chemical reagent composition scheme to have better performance in treating onychomycosis.
It is another object of the present application to provide an ointment for treating onychomycosis, wherein the ointment is more effective in inhibiting germs.
It is another object of the present application to provide an ointment for treating onychomycosis, wherein the ointment is non-irritating to the skin.
It is another object of the present application to provide an ointment for treating onychomycosis, wherein the cost of the ointment is lower.
In order to achieve the purpose, the application provides an ointment for treating onychomycosis, which is prepared from the following raw materials in parts by mass: 5-15 parts of salicylic acid, 5-9 parts of benzoic acid, 15-25 parts of boric acid, 20-30 parts of ketoconazole and 15-25 parts of auxiliary materials, wherein the auxiliary materials are selected from any one or a combination of more of talcum powder, propylene glycol, myristic acid isopropanol, cetyl alcohol, stearyl alcohol and sorbitan stearate.
In the ointment, the ointment is prepared from the following raw materials in parts by mass: 10 parts of salicylic acid, 8 parts of benzoic acid, 20 parts of boric acid, 25 parts of ketoconazole and 18 parts of auxiliary materials
In the ointment, the ointment is prepared from the following raw materials in parts by mass: 10 parts of salicylic acid, 6.4 parts of benzoic acid, 20 parts of boric acid, 26 parts of ketoconazole and 18.8 parts of auxiliary materials.
In the ointment, the auxiliary materials comprise the following raw materials in parts by mass: 50-80 parts of talcum powder, 5-10 parts of propylene glycol, 5-10 parts of myristic acid isopropanol, 5-10 parts of hexadecanol, 5-10 parts of octadecanol and 5-10 parts of sorbitan stearate.
In the ointment, the auxiliary materials comprise the following raw materials in parts by mass: 50 parts of talcum powder, 5 parts of propylene glycol, 5 parts of isopropyl myristate, 5 parts of hexadecanol, 5 parts of octadecanol and 5 parts of sorbitan stearate.
In the ointment, the auxiliary materials comprise the following raw materials in parts by mass: 80 parts of talcum powder, 10 parts of propylene glycol, 10 parts of isopropyl myristate, 10 parts of hexadecanol, 10 parts of octadecanol and 10 parts of sorbitan stearate.
According to the scheme, the application provides the ointment for treating the onychomycosis, wherein the ointment adopts a specific chemical reagent composition scheme so as to have better performance of treating the onychomycosis.
It is another advantage of the present application to provide an ointment for treating onychomycosis, wherein the ointment is more effective in inhibiting pathogens.
It is another advantage of the present application to provide an ointment for treating onychomycosis, wherein the ointment is non-irritating to the skin.
Another advantage of the present application is to provide an ointment for treating onychomycosis, wherein the ointment is less costly.
The ointment for treating onychomycosis prepared by the invention has strong functionality and small toxicity and irritation. Ketoconazole and benzoic acid inhibit fungal reproduction and effectively prevent fungal infection. Salicylic acid has anti-inflammatory and antibacterial effects. The components in the formula supplement each other. Compared with the existing medicines, the ointment has better treatment effect and lower recurrence rate.
Detailed Description
The following description is presented to disclose the application and to enable any person skilled in the art to practice the application. The preferred embodiments in the following description are given by way of example only, and other obvious variations will occur to those skilled in the art. The underlying principles of the application, as defined in the following description, may be applied to other embodiments, variations, modifications, equivalents, and other technical solutions without departing from the spirit and scope of the application.
In the description herein, references to the description of the term "one embodiment," "some embodiments," "an example," "a specific example," or "some examples," etc., mean that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one embodiment or example of the invention. In this specification, the schematic representations of the terms used above are not necessarily intended to refer to the same embodiment or example. Furthermore, the particular features, structures, materials, or characteristics described may be combined in any suitable manner in any one or more embodiments or examples. Furthermore, various embodiments or examples and features of different embodiments or examples described in this specification can be combined and combined by one skilled in the art without contradiction.
Example 1
An ointment for treating onychomycosis is prepared from the following raw materials in parts by mass: 5 parts of salicylic acid, 5 parts of benzoic acid, 15 parts of boric acid, 20 parts of ketoconazole and 15 parts of auxiliary materials, wherein the auxiliary materials are selected from any one or a combination of more of talcum powder, propylene glycol, isopropyl myristate, cetyl alcohol, stearyl alcohol and sorbitan stearate.
The auxiliary material comprises the following raw materials in parts by mass: 50-80 parts of talcum powder, 5-10 parts of propylene glycol, 5-10 parts of myristic acid isopropanol, 5-10 parts of hexadecanol, 5-10 parts of octadecanol and 5-10 parts of sorbitan stearate.
Preferably, the auxiliary materials comprise the following raw materials in parts by mass: 50 parts of talcum powder, 5 parts of propylene glycol, 5 parts of myristic acid isopropanol, 5 parts of hexadecanol, 5 parts of octadecanol and 5-10 parts of sorbitan stearate.
The main components and effects of the invention are as follows:
salicylic acid has antifungal, antipruritic, and cutin dissolving effects, and can be used for treating chronic dermatoses in dermatology, and can stimulate skin and mucosa, and react with protein in organism tissue to make cornea proliferate and peel off, so that the preparation can effectively penetrate into diseased nail.
Benzoic acid has effects in inhibiting growth of fungi, bacteria, and mold, and can be applied topically on skin for treating tinea.
Ketoconazole has antifungal activity, and can be used for treating superficial and deep mycoses, such as skin and nail tinea, vaginal candidiasis albicans, gastrointestinal fungal infections, and systemic infections caused by Candida albicans, coccidioidomycosis, histoplasma, etc.
Boric acid is used as a cleanser for skin lesions, and has the effects of cleaning the skin around the diseased nail and slowing down the spread of fungi.
The stone powder is an additive used in the pharmaceutical industry, has the characteristics of no toxicity, no smell, high whiteness, good compatibility, strong glossiness and strong smoothness, and can not degrade the characteristics of the original product, thereby assisting the permeation of effective components.
Example 2
An ointment for treating onychomycosis is prepared from the following raw materials in parts by mass: 15 parts of salicylic acid, 9 parts of benzoic acid, 25 parts of boric acid, 30 parts of ketoconazole and 25 parts of auxiliary materials.
The auxiliary material comprises the following raw materials in parts by mass: 50-80 parts of talcum powder, 5-10 parts of propylene glycol, 5-10 parts of myristic acid isopropanol, 5-10 parts of hexadecanol, 5-10 parts of octadecanol and 5-10 parts of sorbitan stearate.
Preferably, the auxiliary materials comprise the following raw materials in parts by mass: 50 parts of talcum powder, 5 parts of propylene glycol, 5 parts of myristic acid isopropanol, 5 parts of hexadecanol, 5 parts of octadecanol and 5-10 parts of sorbitan stearate.
The main components and effects of the invention are as follows:
salicylic acid has antifungal, antipruritic, and cutin dissolving effects, and can be used for treating chronic dermatoses in dermatology, and can stimulate skin and mucosa, and react with protein in organism tissue to make cornea proliferate and peel off, so that the preparation can effectively penetrate into diseased nail.
Benzoic acid has effects in inhibiting growth of fungi, bacteria, and mold, and can be applied topically on skin for treating tinea.
Ketoconazole has antifungal activity, and can be used for treating superficial and deep mycoses, such as skin and nail tinea, vaginal candidiasis albicans, gastrointestinal fungal infections, and systemic infections caused by Candida albicans, coccidioidomycosis, histoplasma, etc.
Boric acid is used as a cleanser for skin lesions, and has the effects of cleaning the skin around the diseased nail and slowing down the spread of fungi.
The stone powder is an additive used in the pharmaceutical industry, has the characteristics of no toxicity, no smell, high whiteness, good compatibility, strong glossiness and strong smoothness, and can not degrade the characteristics of the original product, thereby assisting the permeation of effective components.
Example 3
An ointment for treating onychomycosis is prepared from the following raw materials in parts by mass: 15 parts of salicylic acid, 9 parts of benzoic acid, 25 parts of boric acid, 30 parts of ketoconazole and 25 parts of auxiliary materials.
The auxiliary material comprises the following raw materials in parts by mass: 50-80 parts of talcum powder, 5-10 parts of propylene glycol, 5-10 parts of myristic acid isopropanol, 5-10 parts of hexadecanol, 5-10 parts of octadecanol and 5-10 parts of sorbitan stearate.
Preferably, the auxiliary materials comprise the following raw materials in parts by mass: 80 parts of talcum powder, 10 parts of propylene glycol, 10 parts of isopropyl myristate, 10 parts of hexadecanol, 10 parts of octadecanol and 10 parts of sorbitan stearate.
The main components and effects of the invention are as follows:
salicylic acid has antifungal, antipruritic, and cutin dissolving effects, and can be used for treating chronic dermatoses in dermatology, and can stimulate skin and mucosa, and react with protein in organism tissue to make cornea proliferate and peel off, so that the preparation can effectively penetrate into diseased nail.
Benzoic acid has effects in inhibiting growth of fungi, bacteria, and mold, and can be applied topically on skin for treating tinea.
Ketoconazole has antifungal activity, and can be used for treating superficial and deep mycoses, such as skin and nail tinea, vaginal candidiasis albicans, gastrointestinal fungal infections, and systemic infections caused by Candida albicans, coccidioidomycosis, histoplasma, etc.
Boric acid is used as a cleanser for skin lesions, and has the effects of cleaning the skin around the diseased nail and slowing down the spread of fungi.
The stone powder is an additive used in the pharmaceutical industry, has the characteristics of no toxicity, no smell, high whiteness, good compatibility, strong glossiness and strong smoothness, and can not degrade the characteristics of the original product, thereby assisting the permeation of effective components.
Example 4
An ointment for treating onychomycosis is prepared from the following raw materials in parts by mass: 10 parts of salicylic acid, 6.4 parts of benzoic acid, 20 parts of boric acid, 26 parts of ketoconazole and 18.8 parts of auxiliary materials.
The auxiliary material comprises the following raw materials in parts by mass: 50-80 parts of talcum powder, 5-10 parts of propylene glycol, 5-10 parts of myristic acid isopropanol, 5-10 parts of hexadecanol, 5-10 parts of octadecanol and 5-10 parts of sorbitan stearate.
Preferably, the auxiliary materials comprise the following raw materials in parts by mass: 60 parts of talcum powder, 5 parts of propylene glycol, 5 parts of isopropyl myristate, 5 parts of hexadecanol, 6 parts of octadecanol and 5 parts of sorbitan stearate.
The main components and effects of the invention are as follows:
salicylic acid has antifungal, antipruritic, and cutin dissolving effects, and can be used for treating chronic dermatoses in dermatology, and can stimulate skin and mucosa, and react with protein in organism tissue to make cornea proliferate and peel off, so that the preparation can effectively penetrate into diseased nail.
Benzoic acid has effects in inhibiting growth of fungi, bacteria, and mold, and can be applied topically on skin for treating tinea.
Ketoconazole has antifungal activity, and can be used for treating superficial and deep mycoses, such as tinea unguium, vaginal candidiasis albicans, gastrointestinal fungal infections, and systemic infections caused by Candida albicans, coccidioidomycosis, histoplasma bacteria, etc., in a controlled dose within a safe range to better treat onychomycosis without side effects.
Boric acid is used as a cleanser for skin lesions, and has the effects of cleaning the skin around the diseased nail and slowing down the spread of fungi.
The stone powder is an additive used in the pharmaceutical industry, has the characteristics of no toxicity, no smell, high whiteness, good compatibility, strong glossiness and strong smoothness, and can not degrade the characteristics of the original product, thereby assisting the permeation of effective components.
Claims (6)
1. An ointment for treating onychomycosis is characterized by being prepared from the following raw materials in parts by mass: 5-15 parts of salicylic acid, 5-9 parts of benzoic acid, 15-25 parts of boric acid, 20-30 parts of ketoconazole and 15-25 parts of auxiliary materials, wherein the auxiliary materials are selected from any one or a combination of more of talcum powder, propylene glycol, myristic acid isopropanol, cetyl alcohol, stearyl alcohol and sorbitan stearate.
2. The ointment according to claim 1, which is prepared from the following raw materials in parts by mass: 10 parts of salicylic acid, 8 parts of benzoic acid, 20 parts of boric acid, 25 parts of ketoconazole and 18 parts of auxiliary materials.
3. The ointment according to claim 1, which is prepared from the following raw materials in parts by mass: 10 parts of salicylic acid, 6.4 parts of benzoic acid, 20 parts of boric acid, 26 parts of ketoconazole and 18.8 parts of auxiliary materials.
4. The ointment of claim 1, wherein the auxiliary materials comprise the following raw materials in parts by mass: 50-80 parts of talcum powder, 5-10 parts of propylene glycol, 5-10 parts of myristic acid isopropanol, 5-10 parts of hexadecanol, 5-10 parts of octadecanol and 5-10 parts of sorbitan stearate.
5. The ointment of claim 4, wherein the auxiliary materials comprise the following raw materials in parts by mass: 50 parts of talcum powder, 5 parts of propylene glycol, 5 parts of isopropyl myristate, 5 parts of hexadecanol, 5 parts of octadecanol and 5 parts of sorbitan stearate.
6. The ointment of claim 4, wherein the auxiliary materials comprise the following raw materials in parts by mass: 80 parts of talcum powder, 10 parts of propylene glycol, 10 parts of isopropyl myristate, 10 parts of hexadecanol, 10 parts of octadecanol and 10 parts of sorbitan stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911304390.0A CN110876756A (en) | 2019-12-17 | 2019-12-17 | Ointment for treating onychomycosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911304390.0A CN110876756A (en) | 2019-12-17 | 2019-12-17 | Ointment for treating onychomycosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110876756A true CN110876756A (en) | 2020-03-13 |
Family
ID=69731428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911304390.0A Pending CN110876756A (en) | 2019-12-17 | 2019-12-17 | Ointment for treating onychomycosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110876756A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1156407A (en) * | 1994-09-01 | 1997-08-06 | 詹森药业有限公司 | Topical ketoconazole emulsions |
| CN101693040A (en) * | 2009-10-14 | 2010-04-14 | 许保通 | Medicament for treating onychomycosis and preparation method thereof |
| CN108714162A (en) * | 2018-07-19 | 2018-10-30 | 张笑笑 | A kind of external used medicine for treating onychomycosis |
| CN110227100A (en) * | 2019-07-31 | 2019-09-13 | 河南国匠足病医学研究院 | A kind of topical agent for treating onychomycosis |
-
2019
- 2019-12-17 CN CN201911304390.0A patent/CN110876756A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1156407A (en) * | 1994-09-01 | 1997-08-06 | 詹森药业有限公司 | Topical ketoconazole emulsions |
| CN101693040A (en) * | 2009-10-14 | 2010-04-14 | 许保通 | Medicament for treating onychomycosis and preparation method thereof |
| CN108714162A (en) * | 2018-07-19 | 2018-10-30 | 张笑笑 | A kind of external used medicine for treating onychomycosis |
| CN110227100A (en) * | 2019-07-31 | 2019-09-13 | 河南国匠足病医学研究院 | A kind of topical agent for treating onychomycosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2496215B1 (en) | Antimicrobial and anti-acne formulations | |
| EP2429517B1 (en) | Compositions suitable for the topical treatment of fungal infections of the skin and nails | |
| JP6122035B2 (en) | Antifungal composition for the treatment of skin and nails | |
| RU2012149863A (en) | Polysaccharide of tamarind seed for use in the treatment of microbial infections | |
| KR102217617B1 (en) | Pharmaceutical composition for preventing or treating tinea | |
| Tatu et al. | Isolation of Bacillus simplex strain from Demodex folliculorum and observations about Demodicosis spinulosa | |
| US20040209954A1 (en) | Compositions and methods for treating body malodor and fungal overgrowth in mammals | |
| KR101099550B1 (en) | Composition of comprising bee-venoms for treating wounds or burns | |
| US20060105057A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
| US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| US20120219640A1 (en) | Anti-infective solution for athlete's foot | |
| CN110876756A (en) | Ointment for treating onychomycosis | |
| CN102641267A (en) | Externally-applied skin gel as well as preparation method and application thereof | |
| WO2019142124A4 (en) | Pharmaceutical compositions for treatment of vitiligo | |
| JP2017501232A (en) | Keloid reduction using local allantoin | |
| EP3210619A2 (en) | Topical formulation for treating skin or mucosal infections, preparation method and uses thereof | |
| EP3806883B1 (en) | Enhancement of antibacterial actions of a depsipeptide antibiotic using synergistic amounts of boric acid | |
| US20070117825A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
| KR20090071529A (en) | Cosmetic composition comprising vitamin k1 or vitamin k3 for anti-bacterial and anti-fungal bio-activity | |
| EP3378474B1 (en) | Composition for the use in the treatment of plantar hyperhidrosis predisposing to cutaneous fungal infection of the foot | |
| WO2017020036A1 (en) | Composition and related methods for treatment of pilosebaceous diseases | |
| US20040022868A1 (en) | Compositions using tetrasilver tetroxide and methods for management of skin conditions using same | |
| US10905729B1 (en) | Formulations and methods for wound treatment | |
| US11318182B1 (en) | Plant extract for skin infections | |
| CN1471916A (en) | Medicnial composition containing biphenyl lambral for treating superficial mycosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200313 |